Medline Abstracts on CHM

[Guest guest]

Hi All,

 

See:

 

 

Xu R, Li FL, Zhang LL, Song X, Zhu JL, Li B. [Herba Saxifragae

cream in treatment of chronic eczema: a randomized controlled trial.]

[Article in Chinese] Zhong Xi Yi Jie He Xue Bao. 2008 Dec;6(12):1246-

9. Department of Dermatology, Yueyang Hospital of Integrated

Traditional Chinese and Western Medicine, Shanghai University of

Traditional , Shanghai 200437, China; E-mail:

drlibin888 Objective: To explore the clinical efficacy

of Herba Saxifragae cream (HS), a compound of traditional Chinese

herbal medicine, on chronic eczema. Methods: A total of 42 cases of

chronic eczema were randomly divided into HS group (22 cases) and

hydrocortisone (HC) group (20 cases). To the HS group, HS was

externally applied twice a day continuously for 4 weeks. To the HC

group, hydrocortisone was externally applied twice a day continuously

for 4 weeks. The total score of symptom score reducing index (SSRI)

was calculated before and after treatment in terms of itching degree,

lesion shape and lesion area, in the evaluation of the clinical

efficacy of HS on chronic eczema. Results: After 2-week treatment,

the total response rate of HS group was 77.3%, and the total response

rate of HC group was 70.0%. After 4-week treatment, the total

response rates were 86.4% and 85.0% in HS and HC groups respectively.

There was no statistical difference in total scores of SSRI between

the two groups (P>0.05), and neither was there the difference in the

score of itching degree, lesion shape and lesion area (P>0.05).

Conclusion: Herba Saxifragae cream has the same effect as

hydrocortisone in treating chronic eczema. PMID: 19063837 [PubMed -

in process

 

Jiang CY, Wang BE, Chen D. [Protective effect of compound tongfu

granule on intestinal mucosal barrier in patients with cirrhosis of

decompensation stage] [Article in Chinese] Zhongguo Zhong Xi Yi Jie

He Za Zhi. 2008 Sep;28(9):784-7. Beijing Friendship Hospital

Affiliated to Capital Medical Univ, Beijing. jchy12368

OBJECTIVE: To explore the intestinal mucosal barrier protective

effect of herbal medicine Compound Tongfu Granule (CTG) in patients

with liver cirrhosis of decompensation stage. METHODS: Fifty patients

enrolled were randomly assigned to the control group (26 cases) and

the CTG group (24 cases), and 30 healthy adults were set up as normal

control. After 2-week treatment, the intestinal permeability (IP,

represented by urinary lactulose / mannitol excretion rate), plasma

endotoxin (EDT) level, and change of enteric bacteria (EB) in

patients were observed before and after treatment, and compared with

those in the normal control. RESULTS: Before treatment, cirrhotic

patients showed significantly higher levels of IP, EDT, and

intestinal bacilli, but a lower amount of enteric bifidobacteria as

compared with those the normal control. After 2-week treatment,

levels of EDT and urinary excretion rate of lactulose in the CTG

group were lowered more significantly than those in the control group

(P < 0.05), while the amount of bifidobacteria in the CTG group

increased accompanied with intestinal bacilli significantly lowered

to near the levels in the normal control (P < 0.05, P < 0.01).

CONCLUSION: CTG can improve the intestinal barrier function, correct

the intestinal bacteria disturbance, and significantly reduce the

entero-derived endotoxemia in cirrhotic patients of decompensation

stage. PMID: 19065889 [PubMed - in process

Tong GD, Zhou DQ, He JS. [Combined therapy of shehuang paste and

colonic dialysis with Chinese medicines for treatment of refractory

cirrhotic ascites complicated with azotemia] [Article in Chinese]

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Sep;28(9):788-92. Department

of Hepatology, Shenzhen Hospital of Traditional

Affiliated to Guangzhou University of TCM, Guangdong. tgd755

OBJECTIVE: To observe the clinical efficacy of combined therapy

of Shehuang Paste (SHP) with colonic dialysis in treating patients

with refractory cirrhotic ascites complicated with azotemia. METHODS:

Adopting a multi-centered, randomized, double blinded and 1:1

parallel controlled trial, 120 patients were equally randomized into

2 groups, the control group was treated by conventional basic therapy

(umbilical application of placebo paste and colonic dialysis with

normal saline), and the treatment group by, besides the same basic

therapy, umbilical application of SHP once a day and colonic dialysis

with herbal medicine once every other day. The course was 1 month for

both groups. Changes of ascites volume, renal function, serum and

urinary levels of Na+ and K+, blood vasoactive substance, and portal

dynamics in patients before and after treatment were observed.

RESULTS: The total effective rate for ascites was 71.7% (43/60 cases)

in the treatment group and 18.3% (11/60 cases) in the control group,

showing significant difference between groups (P < 0.01). Significant

difference of blood creatinine, urea nitrogen, serum Na+ levels, and

urinary Na+/K+ ratio were shown in the treatment group (P < 0.01)

before and after treatment, and between groups after treatment (P <

0.05, P < 0.01). Portal vein blood flow was significantly lowered in

the treatment group after treatment (P < 0.01), which showed

significant difference as compared with that in the control group (P

< 0.01). Besides, levels of atrial natriuretic peptide, renin,

angiotensin, nitric oxide, and aldosterone decreased and endotoxemia

improved remarkably in the treatment group (P < 0.01). One-year

follow-up showed that the ascites eliminating rate and the incidence

of hepato-renal syndrome in the treatment group was 38.3% (23/60

cases) and 23.3% (14/60 cases) respectively, while in the control

group 0 and 41.7% (25/60 cases) respectively, all showed statistical

difference between groups (all P < 0.05). CONCLUSION: Combined

therapy of SHP and colonic dialysis with herbal medicine could

effectively eliminate the ascites, improve the hemodynamic condition

of portal and splenic veins, reduce the content of vasoactive

substance and noxious substances like ammonia and endotoxin in blood,

and lower the incidence of hepato-renal syndrome. PMID: 19065890

[PubMed - in process]

 

Best regards,